Shares of Danish pharmaceutical large Novo Nordisk slid 2.5% on Friday, extending a 2.7% loss on Thursday as analysts pored over the main points of the agency’s first-quarter outcomes and monitored a possible rival weight reduction remedy.
The corporate reported that gross sales for its blockbuster injectable weight reduction remedy Wegovy, greater than doubled to 9.38 billion Danish kroner ($1.4 billion). Novo Nordisk, which additionally makes diabetes remedy Ozempic, stated the rise in gross sales had offset a slight discount in costs.
Novo Nordisk expects costs to drop additional as new entrants enter the market, CFO Karsten Knudsen stated on a media name, including that the corporate was not seeing a lot proof of Wegovy customers shifting to different rival remedies.
Analysts anticipated even greater weight reduction drug gross sales within the quarter, and a few famous that Novo Nordisk’s 2024 outlook elevate for each gross sales development and working revenue was as a result of one-off accounting changes.
“Whereas we proceed to see Novo as a wide-moat agency, with robust intangible property surrounding its cardiometabolic enterprise, we expect excessive weight problems drug demand and a shortage of provide have pushed share costs above their intrinsic worth,” Karen Andersen, strategist at Morningstar, stated in a Thursday be aware.
The growth in demand for weight reduction remedies noticed Novo Nordisk overtake French luxurious group LVMH to change into Europe’s most useful firm final 12 months. Shares gained 49% in 2023 and are up 25% 12 months up to now.
Gross sales numbers have been “slightly bit gentle, expectations received forward of themselves … and you continue to have these provide challenges at Novo,” Jared Holz, health-care fairness strategist at Mizuho, advised CNBC’s “Quick Cash” on Thursday.
Analysts at Stifel trimmed their goal value on the inventory to 950 kroner, down from 960 kroner on Friday.
Weight reduction drug makers have been in the meantime broadly decrease after U.S. agency Amgen stated it was “very happy” with preliminary trial outcomes for its injectable weight problems remedy MariTide.
The potential enhance in competitors is hanging over each Novo Nordisk and U.S. juggernaut Eli Lilly, which additionally raised its outlook this week, as extra weight reduction gamers emerge to shake up what has largely been a two-horse race.
Each firms are consequently researching new potential weight reduction remedies to take care of an edge.
“After we have a look at your complete area, Novo and Lilly are dominating as a result of they have been already nice current gamers in diabetes. This weight problems market may be very tangential, it is quite simple for them to pivot a really comparable affected person inhabitants to weight problems,” Holz stated.
It is likely to be attainable for newer gamers like Amgen to take 5% to 10% market share over time, or for the totality of opponents to take 10% of the market, however the advance of Eli Lilly and Novo Nordisk is “going to make it actually robust,” Holz added.
Correction: The corporate reported that gross sales for Wegovy greater than doubled to 9.38 billion Danish kroner ($1.4 billion). An earlier model misstated the U.S. greenback determine. Karen Andersen is a strategist at Morningstar. An earlier model misspelled her title.
